Do You Have to Increase Your Mounjaro Dose?

What the titration schedule is asking of you

The six Mounjaro strengths (2.5, 5, 7.5, 10, 12.5 and 15mg) exist on a stepped schedule for a reason. The 2.5mg pen's job is to settle your digestive system, reduce the likelihood of early nausea, and give your body time to adapt to a medicine that slows gastric emptying and activates appetite-regulating hormones. Weight loss at that strength is typically modest. That's by design.

The prescribing schedule described in the Mounjaro SmPC on the eMC recommends moving up roughly every four weeks, which is also what NICE's appraisal of tirzepatide references when describing the titration pathway. The intention is to reach the lowest dose that gives meaningful results with tolerable side effects, for many people that's somewhere between 5mg and 10mg; for others, 15mg is where the medicine really performs.

Thinking of it as a decision tree helps: each four-week period is a checkpoint, not a conveyor belt. If you're tolerating the current dose well and losing weight at a pace that feels right, an increase may be straightforward. If you're struggling with side effects, your prescriber may suggest extending the current strength before moving up, or holding steady. Either path is legitimate. If you're curious about why increasing your Mounjaro dose is considered necessary, there's a full explanation of the clinical logic involved.

When staying at a lower dose makes clinical sense

A common concern (especially for people who found early nausea difficult) is whether they'll be pushed to increase faster than feels comfortable. If you're wondering whether you actually have to increase your Mounjaro dose, the short answer is no. Prescribers can and do recommend holding at a given strength when there are good reasons to.

Side effects are the most common reason to pause. Persistent nausea, vomiting or changes in digestion that haven't settled within a couple of weeks at the current dose are a signal worth discussing before adding more. Rushing upward in that situation rarely helps and often makes things worse.

Weight response also matters. If you're achieving steady, clinically meaningful loss at, say, 5mg, your prescriber might take the view that the risk-benefit balance doesn't yet favour moving higher. The question being asked is always: what dose produces the best outcome for this patient at this point in treatment?

The NHS guidance on weight management injections is clear that clinical oversight matters throughout the titration process, not just at the start. At nume, a prescriber reviews your case before every repeat, that review is where these conversations happen. If you want to talk through where your dose should go next, the place to do that is a free consultation with our team.

The situation where increasing does become important

There is a flip side. Staying at 2.5mg indefinitely without clinical reason is not the same as a planned hold. If the lower doses aren't producing any meaningful change in weight after a reasonable period, and side effects are well-controlled, the evidence base for Mounjaro (including the SURMOUNT-1 trial published in the New England Journal of Medicine, which found average reductions of around 20% at 15mg over 72 weeks) was built on people reaching therapeutic doses, not staying at the starter strength.

NICE's recommendation for tirzepatide, set out in TA1026, notes that if less than 5% weight loss has been achieved after six months at the highest tolerated dose, continuing treatment should be reviewed. The implication is clear: titrating toward the most effective dose you can tolerate is part of what makes this medicine work.

There's also a practical point. Many people find that the appetite-suppressing effect of Mounjaro becomes more pronounced as the dose increases, and it's worth understanding whether going up a dose on Mounjaro is something you need to do to get the most from treatment. Staying lower than necessary can mean getting less of the benefit the medicine is capable of delivering. That's a clinical judgement, not a commercial one, which is why it belongs with a prescriber rather than a forum or a social media group.

What a dose decision looks like in practice at nume

Every prescription issued through nume follows a clinical review by a GPhC-registered Independent Prescriber. That means a real clinician reads your consultation answers and your reported progress, not software making an automated call. For dose increases specifically, evidence of how the current strength is working is part of what the prescriber looks at.

If you order before 12pm on a weekday and your prescriber approves the prescription, treatment is dispatched the same day by DPD. There's no auto-renewal that bumps your dose up automatically; each repeat is considered on its own merits. You can read more about how Mounjaro works as a treatment, or explore other weight loss options if you're still at the research stage. Our clinical team is also there if you have questions that go beyond what a page can answer.

The dose question is genuinely individual. What matters is that whoever is supporting your treatment has enough information to answer it properly, and that the answer is based on your health, not a fixed schedule.